Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 1/20 | 0.58 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.58 |
| ▸ | RHEB | Q15382 | 1/20 | 0.58 |
| ▸ | METAP2 | P50579 | 1/20 | 0.58 |
| ▸ | METAP1 | P53582 | 1/20 | 0.58 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252695 | 0.83 | DGAT1 (0.79) | PKN1PKN2RHEBMETAP2METAP1 | |
| SCHEMBL2360991 | 0.80 | RHEB (0.52) | PKN1PKN2RHEBMETAP2METAP1 | |
| SCHEMBL1250049 | 0.80 | DGAT1 (0.79) | DGAT1CHEK2KDR | |
| SCHEMBL1249718 | 0.79 | DGAT1 (0.71) | DGAT1CHEK2KDR | |
| SCHEMBL20982510 | 0.79 | PKN1 (0.82) | PKN1PKN2RHEBMETAP2METAP1 | |
| SCHEMBL3341423 | 0.78 | PKN1 (0.72) | PKN1PKN2RHEBMETAP2METAP1 | |
| SCHEMBL18764054 | 0.78 | CHEK2 (0.78) | PKN1PKN2RHEBMETAP2METAP1 | |
| SCHEMBL1250479 | 0.78 | GAA (0.65) | METAP2DGAT1CHEK2 | |
| SCHEMBL15252448 | 0.77 | DGAT1 (0.58) | RHEBDGAT1CHEK2JAK2TYK2 | |
| SCHEMBL10188887 | 0.77 | PKN1 (0.54) | PKN1PKN2RHEBMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205595-B1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-8217065-B2 | Organic compounds | NOVARTIS AG (SE) | 2012-07-10 | — | — | US | disclosed |
| US-20110077277-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-7879850-B2 | such as 6-[5-(4-Chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-(2,6-dichloro-phenyl)-1H-benzoimidazole, having diacylglycerol O-acyl transferase inhibitory activity, used for the treatment of impaired glucose tolerance, non-insulin dependent diabetes or obesity | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| EP-2205595-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077277-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | PKN1 3372/4885PKN2 3915/4885RHEB 1637/4885 |
| US-20090186891-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | PKN1 3372/4885PKN2 3915/4885RHEB 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.